National Evaluation of the Adherence to Recommendations of Venous Thrombo Embolism Treatment in Cancer Patients

Study Overview
=================
Brief Summary
-----------------
Treatment of venous thromboembolism in cancer patients is specific and has been validated in trials that favor the use of LMWH (Low Molecular Weight Heparin) instead of VKA (Vitamin K Antagonist) treatment during 6 months. International recommendations have diffused this option.It is necessary to evaluate the compliance of physicians to this treatment by measuring the number of patients with cancer treated with long term use of LMWH.

Official Title
-----------------
National Evaluation of the Adherence to Recommendations of VTE Treatment in Cancer Patients

Conditions
-----------------
Neoplasms, Venous Thromboembolism

Intervention / Treatment
-----------------
* Procedure: VTE treatment in cancer patient description


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All patients with cancer present in the clinic, hospital, out patients diagnosed with a VTE during the 6 previous months. VTE can be symptomatic or asymptomatic, can be located close to a central line, and of any type (DVT, PE, SVT) Exclusion Criteria: Patient already included in a trial studying antithrombotic therapy Patient refusing the study Patient under 18 and/or not competent to give informed consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| VTE treatment in cancer patient<br>All patients with cancer present in the clinic, hospital, out patient diagnosed with a VTE during the 6 previous months. | Procedure: VTE treatment in cancer patient description<br>* proportion of patients treated for evolutive VTE according to international recommendations<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Evaluation of the adherence to recommendations of VTE treatment in cancer patients | Proportion of patients treated for evolutive VTE according to international recommandations Patients could be hospitalised or could be out patient | At baseline (J0) | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Evaluation of VTE disease according to cancer diagnosis (proportion of SVT (Superficial Venous Thrombosis), DVT (Deep Venous Thrombosis), PE (Pulmonary Embolism) | Percentage of VTE (PE,DVT,SVT)and cancer type | At baseline (J0) | 
| Proportion of asymptomatic VTE disease for this population | percentage of VTE and cancer status (local, metastatic) | At baseline (J0) | 
| Feasibility of self injections for VTE treatment in cancer patients. | percentage of patients practising self injections | At baseline (J0) | 
| Proportion of patients with catheter thrombosis | Percentage of patients receiving novel cancer therapies | At baseline (J0) | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
PE, DVT, SVT, LMWH, VKA, international Venous Thromboembolism Recommendations